Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class H (HK:0874)
:0874
Want to see HK:0874 full AI Analyst Report?
Total Valuation
Guangzhou Baiyunshan Pharmaceutical Holdings Company has a market cap or net worth of HK$38.68B. The enterprise value is HK$46.15B.
Market CapHK$38.68B
Enterprise ValueHK$46.15B
Share Statistics
Guangzhou Baiyunshan Pharmaceutical Holdings Company has 219,900,000 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding219,900,000
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Guangzhou Baiyunshan Pharmaceutical Holdings Company’s return on equity (ROE) is 0.08 and return on invested capital (ROIC) is 4.81%.
Return on Equity (ROE)0.08
Return on Assets (ROA)0.04
Return on Invested Capital (ROIC)4.81%
Return on Capital Employed (ROCE)0.08
Revenue Per Employee2.76M
Profits Per Employee103.27K
Employee Count28,138
Asset Turnover0.92
Inventory Turnover4.95
Valuation Ratios
The current PE Ratio of Guangzhou Baiyunshan Pharmaceutical Holdings Company is 12.0. Guangzhou Baiyunshan Pharmaceutical Holdings Company’s PEG ratio is 1.68.
PE Ratio12.0
PS Ratio0.33
PB Ratio0.68
Price to Fair Value0.68
Price to FCF-27.11
Price to Operating Cash Flow18.02
PEG Ratio1.68
Income Statement
In the last 12 months, Guangzhou Baiyunshan Pharmaceutical Holdings Company had revenue of 77.66B and earned 2.98B in profits. Earnings per share was 1.83.
Revenue77.66B
Gross Profit12.52B
Operating Income3.63B
Pretax Income3.69B
Net Income2.98B
EBITDA3.95B
Earnings Per Share (EPS)1.83
Cash Flow
In the last 12 months, operating cash flow was 1.91B and capital expenditures -1.24B, giving a free cash flow of 666.92M billion.
Operating Cash Flow1.91B
Free Cash Flow666.92M
Free Cash Flow per Share3.03
Dividends & Yields
Guangzhou Baiyunshan Pharmaceutical Holdings Company pays an annual dividend of HK$0.516, resulting in a dividend yield of 7.15%
Dividend Per ShareHK$0.516
Dividend Yield7.15%
Payout Ratio26.74%
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.66
52-Week Price Change-8.38%
50-Day Moving Average15.83
200-Day Moving Average17.45
Relative Strength Index (RSI)46.56
Average Volume (3m)908.48K
Important Dates
Guangzhou Baiyunshan Pharmaceutical Holdings Company upcoming earnings date is Aug 14, 2026, TBA (Confirmed).
Last Earnings DateApr 27, 2026
Next Earnings DateAug 14, 2026
Ex-Dividend Date―
Financial Position
Guangzhou Baiyunshan Pharmaceutical Holdings Company as a current ratio of 1.57, with Debt / Equity ratio of 59.38%
Current Ratio1.57
Quick Ratio1.24
Debt to Market Cap0.79
Net Debt to EBITDA1.46
Interest Coverage Ratio8.72
Taxes
In the past 12 months, Guangzhou Baiyunshan Pharmaceutical Holdings Company has paid 629.22M in taxes.
Income Tax629.22M
Effective Tax Rate0.17
Enterprise Valuation
Guangzhou Baiyunshan Pharmaceutical Holdings Company EV to EBITDA ratio is 8.00, with an EV/FCF ratio of -33.14.
EV to Sales0.41
EV to EBITDA8.00
EV to Free Cash Flow-33.14
EV to Operating Cash Flow124.77
Balance Sheet
Guangzhou Baiyunshan Pharmaceutical Holdings Company has HK$12.29B in cash and marketable securities with HK$17.04B in debt, giving a net cash position of -HK$4.75B billion.
Cash & Marketable SecuritiesHK$12.29B
Total DebtHK$17.04B
Net Cash-HK$4.75B
Net Cash Per Share-HK$21.60
Tangible Book Value Per ShareHK$22.83
Margins
Gross margin is 16.00%, with operating margin of 4.67%, and net profit margin of 3.84%.
Gross Margin16.00%
Operating Margin4.67%
Pretax Margin4.75%
Net Profit Margin3.84%
EBITDA Margin5.09%
EBIT Margin3.89%
Analyst Forecast
The average price target for Guangzhou Baiyunshan Pharmaceutical Holdings Company is HK$23.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price TargetHK$23.00
Price Target Upside22.67% Upside
Analyst ConsensusModerate Buy
Analyst Count1
Revenue Growth Forecast7.32%
EPS Growth Forecast12.84%